专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2011049350A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1多肽或其片段及其制备方法
公开(公告)号：WO2011049350A3
公开(公告)日：2011-10-13
申请号：PCT/KR2010007160
申请日：2010-10-19
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , C12N15/28 , C12N15/63
CPC分类号： C07K14/70578
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
摘要翻译：本发明涉及体内或离体与肿瘤坏死因子偶联的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出对体内蛋白酶活性的改善的抗性，并因此表现出改善的生物利用度和改善的吸收率。

32. 发明申请

WO2010085086A3 MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND MANUFACTURING METHOD THEREOF 审中-公开
标题翻译：改性人类血小板聚糖片段及其制造方法
公开(公告)号：WO2010085086A3
公开(公告)日：2010-12-09
申请号：PCT/KR2010000368
申请日：2010-01-20
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , JEONG JAE KAP , LEE SUNG YUL , SONG YEON JUNG , SHIM WON JO
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , JEONG JAE KAP , LEE SUNG YUL , SONG YEON JUNG , SHIM WON JO
IPC分类号： C07K14/505 , A61K38/17 , C12N15/12 , C12N15/63
CPC分类号： C07K14/515 , A61K38/196
摘要： The present invention provides a modified human thrombopoietin polypeptide fragment that has platelet proliferative activity in vivo and in vitro and enhanced resistance to protease existing in vivo.
摘要翻译：本发明提供了在体内和体外具有血小板增殖活性的改良人类血小板生成素多肽片段，并增强了体内存在蛋白酶的抗性。

33. 发明申请

WO2010077096A3 DRUG DELIVERY SYSTEM 审中-公开
标题翻译：药物输送系统
公开(公告)号：WO2010077096A3
公开(公告)日：2010-11-25
申请号：PCT/KR2009007968
申请日：2009-12-30
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
IPC分类号： A61J3/06 , A61J3/00
CPC分类号： A61J3/071 , A61M31/002
摘要： The present invention relates to a drug delivery system comprising: a plastic soft capsule having an enclosed space defined therein; a tablet to be kept in the interior space of the capsule; and a drug filling portion, wherein part of the tablet's surface is adhered closely to the inside surface of the capsule and the drug filling portion is composed of the remaining area of the interior space excluding the space occupied by the tablet. Examples of benefits of a drug delivery system according to the present invention include a system which is capable of controlling drug release, physically separating and then filling the same or different active ingredients contained in the system to prevent chemical reactions induced by physical blending of those ingredients, preventing interaction between drugs that can occur inside the body when different kinds of drugs are co-administered, and storing a large amount of active ingredients.
摘要翻译：药物输送系统技术领域本发明涉及一种药物输送系统，其包括：塑料软胶囊，其中限定有封闭空间; 将片剂保存在胶囊的内部空间中; 和药物填充部分，其中片剂表面的一部分紧密地粘附到胶囊的内表面，并且药物填充部分由除了片剂占据的空间之外的内部空间的剩余区域组成。根据本发明的药物递送系统的益处的实例包括能够控制药物释放，物理分离然后填充系统中包含的相同或不同活性成分以防止由这些成分物理混合诱导的化学反应的系统，当联合施用不同种类的药物时，防止在体内可能发生的药物之间的相互作用，并且储存大量的活性成分。

34. 发明申请

WO2011083999A2 BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT 审中-公开
标题翻译： BIGUANIDE衍生物，其制备方法和含有作为活性成分的药物组合物
公开(公告)号：WO2011083999A2
公开(公告)日：2011-07-14
申请号：PCT/KR2011000098
申请日：2011-01-06
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , MIN CHANG HEE , PARK SE HWAN , KIM YONG EUN , KIM DUCK , LEE JI SUN , OH JU HOON
发明人： KIM SUNG WUK , JUN SUNG SOO , MIN CHANG HEE , PARK SE HWAN , KIM YONG EUN , KIM DUCK , LEE JI SUN , OH JU HOON
IPC分类号： C07C279/26 , A61K31/155 , A61P3/10 , A61P35/00 , C07C277/00
CPC分类号： A61K31/155 , A61K31/341 , A61K31/4406 , A61K31/472 , C07C277/04 , C07C279/04 , C07C279/06 , C07C279/08 , C07C279/16 , C07C279/18 , C07C279/26 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2603/74 , C07D213/38 , C07D307/52 , C07D317/58 , C07D333/20
摘要： The present invention provides a biguanide derivative or pharmaceutically acceptable salt thereof represented by Formula 1 with N4-N5-substitutions, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient. Compared with conventional drugs, even a small amount of the biguanide derivative of the present invention exhibits excellent effects of AMPKa activation and inhibition of cancer cell proliferation, which makes it useful for the treatment of diabetes, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer and the like.
摘要翻译：本发明提供由式1表示的具有N4-N5取代基的双胍衍生物或其药学上可接受的盐，其制备方法和含有双胍衍生物作为活性成分的药物组合物。与常规药物相比，即使少量本发明的双胍衍生物也表现出AMPKa活化和癌细胞增殖抑制作用的优异性，因此可用于治疗糖尿病，肥胖症，高脂血症，高胆固醇血症，脂肪肝，冠心病动脉疾病，骨质疏松症，多囊卵巢综合征，代谢综合征，癌症等。

35. 发明申请

WO2012036410A2 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1多肽或其片段及其制备方法
公开(公告)号：WO2012036410A2
公开(公告)日：2012-03-22
申请号：PCT/KR2011006621
申请日：2011-09-07
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , A61K38/19 , C07K14/525 , C12N15/63
CPC分类号： C07K14/7151 , A61K38/00 , A61K38/19 , C07K14/525 , C07K14/705 , C12N15/63
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to bind to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. According to the present invention, the modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof exhibits improved binding force to the tumor necrosis factor.
摘要翻译：本发明涉及在体内或离体结合肿瘤坏死因子的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明，修饰的人肿瘤坏死因子受体-1多肽或其片段表现出对肿瘤坏死因子的改善的结合力。

36. 发明申请

WO2011083998A3 BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT 审中-公开
标题翻译：双胍衍生物及其制备方法和含有双胍衍生物作为活性成分的药物组合物
公开(公告)号：WO2011083998A3
公开(公告)日：2011-10-27
申请号：PCT/KR2011000097
申请日：2011-01-06
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , MIN CHANG HEE , KIM YOUNG WOONG , KANG MIN SEOK , OH BYUNG KYU , PARK SE HWAN , KIM YONG EUN , KIM DUCK , LEE JI SUN , OH JU HOON
发明人： KIM SUNG WUK , JUN SUNG SOO , MIN CHANG HEE , KIM YOUNG WOONG , KANG MIN SEOK , OH BYUNG KYU , PARK SE HWAN , KIM YONG EUN , KIM DUCK , LEE JI SUN , OH JU HOON
IPC分类号： C07C279/26 , A61K31/155 , A61P3/10 , A61P35/00 , C07C277/02
CPC分类号： A61K31/155 , A61K31/341 , A61K31/4406 , A61K31/472 , C07C277/04 , C07C279/04 , C07C279/06 , C07C279/08 , C07C279/16 , C07C279/18 , C07C279/26 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2603/74 , C07D213/38 , C07D307/52 , C07D317/58 , C07D333/20
摘要： The present invention provides a biguanide derivative or pharmaceutically allowable salt thereof represented by Formula 1 with N1-N5 substitution, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient. Compared with conventional drugs, even a small amount of the biguanide derivative of the present invention exhibits excellent effects of AMPKa activation and inhibition of cancer cell proliferation, which makes it useful for the treatment of diabetes, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer and the like.
摘要翻译：本发明提供由式1表示的双胍衍生物或其药学允许的盐以及N1-N5取代物，其制备方法和含有该双胍衍生物作为活性成分的药物组合物。与常规药物相比，即使少量本发明的双胍衍生物也表现出优异的AMPKα活化作用和抑制癌细胞增殖的作用，这使其可用于治疗糖尿病，肥胖症，高脂血症，高胆固醇血症，脂肪肝，冠状动脉动脉疾病，骨质疏松症，多囊卵巢综合征，代谢综合征，癌症等。

37. 发明申请

WO2010044581A3 N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 审中-公开
标题翻译： N1-苯并[1,3]二氧戊环-5-基甲基-N2取代的双胍衍生物，其制备方法和含有该化合物的药物组合物
公开(公告)号：WO2010044581A3
公开(公告)日：2010-07-22
申请号：PCT/KR2009005855
申请日：2009-10-13
申请人： HANALL BIOPHARMA CO LTD , KOREA RES INST CHEM TECH , KIM SUNG WUK , JUN SUNG SOO , CHEON HYAE GYEONG , KIM KWANG ROK , RHEE SANG DAL , JUNG WON HOON , LEE JONG CHEOL
发明人： KIM SUNG WUK , JUN SUNG SOO , CHEON HYAE GYEONG , KIM KWANG ROK , RHEE SANG DAL , JUNG WON HOON , LEE JONG CHEOL
IPC分类号： C07D317/48
CPC分类号： C07D317/58
摘要： The present invention relates to an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative expressed in chemical formula 1, to a pharmaceutically acceptable salt thereof, to a preparation method thereof, and to a pharmaceutical composition containing the same as an active ingredient. The N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of the present invention shows superior hypoglycemic action and superior hypolipidemic action even at a lower dosage as compared with conventional drugs, and thus can be used for the prevention and treatment of metabolic syndrome disorders such as diabetes, non-insulin-dependent diabetes, obesity, arteriosclerosis, and the like, or cancer involving P53 gene deficiency.
摘要翻译：化学式1表示的N 1 - 苯并[1,3]间二氧杂环戊烯-5-基甲基-N 2 - 取代的双胍衍生物及其药学上可接受的盐，其制备方法和含有该化合物的药物组合物与有效成分相同。与常规药物相比，本发明的N1-苯并[1,3]间二氧杂环戊烯-5-基甲基-N2-取代的双胍衍生物即使在较低剂量下也显示出优异的降血糖作用和优异的降血脂作用，因此可用于糖尿病，非胰岛素依赖型糖尿病，肥胖症，动脉硬化等代谢综合症的预防和治疗，或涉及P53基因缺陷的癌症。

38. 发明申请

WO2009104932A2 COMPOSITE PREPARATION 审中-公开
标题翻译：复合制剂
公开(公告)号：WO2009104932A2
公开(公告)日：2009-08-27
申请号：PCT/KR2009000832
申请日：2009-02-21
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK
IPC分类号： A61K9/52
CPC分类号： A61K9/2077 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4365 , A61K31/60 , A61K31/616 , A61K2300/00
摘要： The present invention provides a composite preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active component; and a delayed-release section comprising clopidogrel, an isomer thereof or a pharmaceutically acceptable salt thereof as a pharmacologically active component. The composite preparation of the present invention exhibits a far better effect in preventing platelet aggregation than does simultaneous oral therapy or treatment with the respective single preparations, and not only can it improve the patient's drug-taking compliance by administration once a day but it can also reduce the adverse reactions which follow long-term administration of aspirin. The composite preparation of the present invention is also advantageous in that it exhibits an outstanding effect in inhibiting blood platelet aggregation despite a reduction in the amount of aspirin ingested, and in that it converts clopidogrel resistance into susceptibility and prevents serious adverse reactions caused by clopidogrel resistance and in that it can be stored over the longer term since it is stable under common storage conditions.
摘要翻译：本发明提供一种复合制剂，其包括：包含阿司匹林或其药学上可接受的盐作为药理活性成分的预释放部分; 以及包含氯吡格雷，其异构体或其药学上可接受的盐作为药理活性成分的延迟释放部分。本发明的复合制剂与单独使用的制剂同时进行口服治疗或治疗相比，具有更好的预防血小板聚集效果，并且不仅可以通过一天一次的给药来改善患者的药物依从性，而且还可以减少长期服用阿司匹林后的不良反应。本发明的复合制剂的优点还在于，尽管阿司匹林的摄入量减少，但其表现出抑制血小板聚集的突出效果，并且其将氯吡格雷耐药性转化为易感性并防止由氯吡格雷抗性引起的严重不良反应并且由于它在通常的储存条件下是稳定的，因此可以长期储存。

39. 发明申请

WO2009134057A3 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译：含有血管紧张素II受体阻断剂的药物制剂
公开(公告)号：WO2009134057A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002225
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理学活性成分的药剂，并且延长释放室具有血管紧张素-II受体阻断剂作为药理学活性成分。本发明的制剂使药物和临床上降低血压的效果最大化并且在服用制剂时预防并发症，有助于避免与由肝脏中的相同酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

40. 发明申请

WO2009104916A2 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009104916A2
公开(公告)日：2009-08-27
申请号：PCT/KR2009000803
申请日：2009-02-21
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
IPC分类号： A61K9/52
CPC分类号： A61K9/2866 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/2095 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K9/5084 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical formulation, which comprises a pre-release portion containing HMG-CoA (hydroxymethylglutaryl-CoA) reductase as a pharmacologically active component, and a sustained-release portion containing bis-dihydropyridine-class calcium-channel blocker as a pharmacologically active component. The formulation of the invention offers synergy effects through co-administration of the bis-dihydropyridine-class calcium-channel blocker/HMG-CoA (hydroxymethylglutaryl-CoA) reductase, and induces the time-dependent absorption, metabolism and mechanism of individual drug through the controlled release to avoid competitive antagonistic interactions between drugs, thus maximizing effects of each pharmacologically active component while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once per day.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的HMG-CoA（羟甲基戊二酰-CoA）还原酶的预释放部分和含有双 - 二氢吡啶类钙通道阻断剂作为药理活性的缓释部分零件。本发明的制剂通过双 - 二氢吡啶类钙通道阻断剂/ HMG-CoA（羟甲基戊二酰辅酶A）还原酶的共同给药提供了协同效应，并且引起了单个药物的时间依赖性吸收，代谢和机制控制释放以避免药物之间的竞争性拮抗相互作用，从而最大化每种药理活性成分的作用，同时尽量减少副作用，例如肌病的风险，并且通过每天服用一片药物来显着增加患者的依从性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式